2-FMA Pellets – 50mg
€ 10,25 – € 1.750,00Price range: € 10,25 through € 1.750,00
2-FMA Pellets 50mg are described as compressed research preparations associated with 2-fluoromethamphetamine, an ortho-fluorinated derivative of methamphetamine.
The named compound belongs to the substituted amphetamine family and contains a fluorine substituent at the 2-position of its aromatic ring.
The supplied source identifies solid pressed pellets with a labeled analyte quantity of 50mg per finished unit.
This quantity has not been independently verified through finished-unit testing.
The described research context includes chemical identity assessment, chromatographic characterization, structural comparison, and investigation of substituted amphetamine analogs.
The source reports CAS number 1780004-19-4 and molecular formula C10H14FN for the neutral compound, corresponding to approximately 167.22 g/mol.
It also refers to possible hydrochloride-salt presentation, component purity of at least 98%, third-party testing, batch tracking, and ISO-aligned manufacturing.
No actual batch-specific analytical reports or manufacturing certifications were supplied.
Chemical form, stereochemical identity, ingredient purity, finished-unit content, content uniformity, excipients, and storage stability remain unverified.
The pellets are not established as certified reference materials or validated quantitative calibration standards.
For research use only. Not for human or veterinary use. Not for clinical, diagnostic, or consumptive applications.
2-FMA Pellets 50mg – Fluoromethamphetamine Research Material
2-FMA Pellets 50mg – Product Overview
2-FMA Pellets 50mg is the supplied catalog designation for a compressed-pellet research preparation associated with 2-fluoromethamphetamine.
The named compound belongs to the substituted amphetamine family and is structurally related to methamphetamine and other N-methylated phenethylamine derivatives.
Its molecular structure contains a fluorine substituent at the ortho position of the aromatic ring.
The supplied source describes solid pressed pellets with a labeled analyte quantity per finished unit.
This labeled amount is a source-provided specification rather than an independently confirmed analytical measurement.
No finished-unit assay, content-uniformity study, or batch-specific quantitative report accompanied the information.
The source positions the preparation for controlled analytical and non-clinical laboratory research.
The stated scientific contexts include chemical identification, chromatographic characterization, structural comparison, and investigation of related substituted amphetamines.
These research contexts should not be confused with verified analytical performance of the actual finished pellets.
The supplied information also refers to independent testing, batch records, and Certificate of Analysis documentation.
However, no supporting laboratory certificates or batch-specific analytical results were provided.
The finished preparation is not established as a certified reference material, validated quantitative calibrator, or approved pharmaceutical product.
Chemical Identity & Classification
The supplied source identifies 2-FMA as 2-fluoromethamphetamine.
It is an ortho-fluorinated methamphetamine analog belonging to the substituted amphetamine family. 2-FMA Pellets – 50mg
The fluorine substituent distinguishes the named compound from methamphetamine and related positional analogs.
The supplied chemical information includes:
- Common designation: 2-FMA
- Descriptive chemical name: 2-Fluoromethamphetamine
- Systematic chemical name: 1-(2-Fluorophenyl)-N-methylpropan-2-amine
- Reported CAS Registry Number: 1780004-19-4
- Reported molecular formula for neutral compound: C10H14FN
- Calculated molecular weight for neutral compound: Approximately 167.22 g/mol
- Chemical classification: Fluorinated N-methyl substituted amphetamine
- Reported presentation: Solid pressed pellets
- Labeled analyte amount: 50mg per finished pellet
- Intended designation: Research Use Only
The reported molecular formula and calculated molecular weight are internally consistent for neutral 2-FMA. 2-FMA Pellets – 50mg
However, the source also states that the material is often supplied as a hydrochloride salt.
The actual chemical form of this product has not been established.
A hydrochloride salt would have a different formula and molecular weight from the neutral compound.
The source also does not identify the stereochemical composition of the material.
These distinctions matter because substituted amphetamines can exhibit stereochemical variation.
The reported CAS number differs from another supplier-provided identifier previously associated with 2-FMA.
That discrepancy should be resolved against verified structural records before definitive publication.
The molecular structure of the named compound does not establish the composition of the finished pellet.
Additional formulation components may be present, but no excipient specification was supplied.
Researchers may consult PubChem for public chemical-reference information, ensuring that any selected record corresponds to the actual molecular structure, stereochemistry, and chemical form.
Chemical & Physical Characteristics
The supplied source describes the product as off-white to light-beige compressed pellets of uniform appearance.
No actual product-specific physical inspection report, image verification, or batch appearance record was supplied.
The reported appearance therefore remains a supplier-provided description.
A compressed pellet is a finished preparation that may contain the named analyte together with additional formulation components.
The source does not identify pellet dimensions, total unit mass, compression characteristics, excipient composition, or manufacturing method.
The named compound contains an ortho-fluorinated aromatic group and an N-methyl substituent within its substituted amphetamine molecular framework.
These structural features distinguish 2-FMA from methamphetamine and from related positional fluorinated analogs.
The source describes general solubility in common organic solvents.
However, no product-specific solubility measurements, solvent compatibility records, or finished-pellet extraction studies were supplied.
No validated dissolution, recovery, or stability data were provided for the complete preparation.
The source also does not establish whether the analyte is distributed uniformly within each finished pellet.
Consequently, no definitive claim is made about the physical behavior or analytical recovery of the finished preparation.
Purity & Analytical Verification
The supplied source claims typical ingredient purity of at least 98%.
It also refers to independent analytical verification.
No actual batch-specific Certificate of Analysis, chromatogram, mass spectrum, NMR spectrum, impurity profile, or independent laboratory report was supplied.
The claimed purity therefore remains unverified.
For 2-FMA Pellets 50mg, ingredient purity and finished-unit composition are separate analytical characteristics.
An ingredient-purity result does not independently establish the actual quantity of analyte in a finished pellet.
Likewise, the labeled analyte amount does not establish content uniformity across a batch.
The source refers to HPLC, GC-MS, LC-MS/MS, and NMR spectroscopy as analytical techniques relevant to characterization.
However, no product-specific results were supplied demonstrating identification, purity assessment, or quantitative recovery of 2-FMA from the finished preparation.
The source does not establish a validated quantitative method, assigned reference value, or measurement uncertainty.
It also does not establish whether the claimed purity refers to a neutral compound, a salt, or a specific batch.
The preparation should therefore not be described as a certified quantitative reference standard.
Any definitive claims about purity, identity, composition, or uniformity require supporting analytical records for the actual batch.
Quality Control & Batch Integrity
The source refers to third-party testing, batch-specific tracking, complete documentation, and ISO-aligned production conditions.
These are supplier-provided quality-assurance claims.
No actual third-party report, batch record, manufacturing audit, or ISO certification was supplied.
The claims therefore remain unverified. 2-FMA Pellets – 50mg
For a finished-pellet preparation, batch documentation should distinguish the identity and analytical characteristics of the named ingredient from the characteristics of the complete unit.
The source does not establish whether the labeled analyte quantity was independently measured after formulation.
It also does not provide evidence of finished-unit content uniformity or batch-to-batch consistency.
For 2-FMA Pellets 50mg, the distinction between nominal analyte content and verified finished-unit composition is particularly important.
The Research Use Only designation describes intended positioning but does not independently demonstrate quality, traceability, or validated analytical performance.
Claims concerning independent verification, ISO alignment, and batch consistency should be supported by actual records.
Safety, Handling & Laboratory Precautions
2-FMA is a synthetic substituted amphetamine associated with stimulant-class pharmacological activity and toxicological uncertainty.
The supplied source does not provide a complete product-specific toxicological assessment.
Laboratory personnel should consult applicable chemical-safety documentation and institutional procedures before receiving or examining the material.
Relevant precautions include restricted access, appropriate protective equipment, contamination prevention, accidental-exposure procedures, and chemical-waste management.
The compressed-pellet presentation does not establish safety for human or veterinary exposure.
The material should remain secured against unauthorized access and separated from food, beverages, and non-research environments.
Because the actual chemical form, ingredient purity, excipient composition, and finished-unit content have not been independently confirmed, laboratory records should clearly distinguish supplier-provided specifications from verified findings.
Any accidental exposure or contamination incident should be managed according to institutional emergency procedures.
Packaging, Labeling & Storage
The supplied source describes light-resistant, moisture-resistant packaging, batch-aware handling, tracking, and professional shipment arrangements.
No actual packaging specification, container-validation report, or shipment-condition record was supplied.
The source recommends storage in a cool, dry, low-humidity environment protected from light.
It also suggests refrigeration at approximately 2–8°C.
No validated stability study was provided for the finished-pellet preparation.
The suggested temperature range therefore cannot be presented as a verified requirement or as evidence of a particular shelf life.
For 2-FMA Pellets 50mg, laboratory inventory records should preserve the product designation, any available batch identifier, receipt details, and relevant storage observations.
The labeled analyte quantity should be recorded as a source-provided specification unless independently verified. 2-FMA Pellets – 50mg
Packaging and environmental requirements should be assessed using available safety documentation, relevant stability evidence, and institutional procedures.
Intended Research Use & Market Positioning
The supplied scientific context places 2-FMA within analytical research involving substituted amphetamine chemical identity, aromatic fluorination, and comparative structural characterization.
The ortho-fluoro substituent provides a distinguishing structural feature relevant to chemical analysis.
The source describes interest in chromatographic characterization, forensic analytical studies, and investigation of related substituted amphetamines.
However, no product-specific analytical validation, transporter-binding dataset, or stability study was supplied for the actual pellets.
The Raw Lab Chems catalog identifies 2-FMA Pellets as the product listing discussed here.
For related chemical-family and presentation context, the supplied source also identifies 2-FMA Capsules and 2-FA Pellets.
The first related listing refers to the same named compound in a different finished preparation.
The second refers to a distinct fluorinated amphetamine analog without the N-methyl substituent present in 2-FMA. 2-FMA Pellets – 50mg
2-FMA and 2-FA should not be treated as chemically identical or analytically interchangeable.
The supplied information does not establish equivalent chemical purity, finished-unit content, excipient composition, or analytical performance across these products.
These catalog references should not be interpreted as evidence of certified reference-material status or validated quantitative equivalence.
Ordering, Availability & Fulfillment
The supplied source describes professional packaging, international shipping, tracking, and secure handling arrangements.
No current inventory record, confirmed pack-size listing, carrier agreement, shipment authorization, or verified delivery information was supplied.
Consequently, no availability, delivery-time, customs-clearance, or transportation-compliance guarantee is asserted.
2-FMA may be subject to controlled-substance, analogue, pharmaceutical, or other chemical regulations depending on the jurisdiction.
Institutional acquisition, possession, transportation, importation, and exportation must be assessed under applicable laws.
Research-only labeling does not establish a legal exemption.
Legal & Regulatory Disclaimer
For research use only. Not for human or veterinary use. Not for clinical, diagnostic, or consumptive applications.
2-FMA is a synthetic substituted amphetamine whose possession, acquisition, transfer, transportation, importation, exportation, and laboratory investigation may be restricted or prohibited depending on the jurisdiction. 2-FMA Pellets – 50mg
The supplied information does not establish universal legal status or regulatory authorization.
Institutions remain responsible for determining applicable legal requirements and obtaining any necessary permissions.
No medical approval, consumer-use authorization, or regulatory exemption is implied by this description.
| Quantity (pellets) |
5 ,10 ,25 ,50 ,100 ,250 ,500 ,1000 ,2500 |
|---|
You must be logged in to post a review.

Reviews
There are no reviews yet.